California Proposition 38 would authorize $8.4 billion in immunology research bonds
On today's ballot: a measure letting California borrow $8.4 billion for immunology and immunotherapy research, half for a University of California-affiliated institute and half for competitive grants.
Among the questions on California's ballot in today's election is Proposition 38, an initiative statute whose official title reads: "Authorizes Bonds For Immunology Medical Research. Initiative Statute." [s1] It reached the 3 November 2026 ballot through petition signatures [s1][s3].
This explainer covers what the measure would authorize, how the money would be split, and what it would cost to repay, using only the state's official voter materials. It does not describe how the vote is expected to go.
What a vote would decide
The measure would, in the words of the analysis, "allow the state to issue an $8.4 billion general obligation bond" for immunology and immunotherapy research [s2]. A general obligation bond is money the state borrows and repays over time from its general fund.
The official summary of a Yes vote: "The state could borrow $8.4 billion to support medical research in immunology and immunotherapy" conducted by California research institutes and universities [s1]. A No vote: "The state could not borrow $8.4 billion to support medical research in immunology and immunotherapy" [s1].
How the $8.4 billion would be divided
The analysis describes a two-part split. "About half of the bond funds would go to a research institute" specializing in immunology and immunotherapy [s2]. The California Department of Public Health would select that institute, which must meet criteria including "collaboration with a University of California (UC) campus" [s2].
The other half would flow through a council that would "give out the other half of bond funds as competitive research grants" [s2]. In other words, one portion is directed to a single designated institute and the other is awarded by competition.
What the fields mean
The analysis defines the science in plain terms. Immunology is "the study of the body's immune system and how it protects the body from abnormal cells" [s2]. Immunotherapy refers to developing "treatments that help the immune system fight diseases more effectively" [s2].
Those fields sit behind a wide span of modern medicine — cancer treatment, autoimmune disease and infection among them — which is why a bond aimed at them is a public-health-research question rather than a narrow one.
What it would cost to repay
Borrowing is not free, and the official materials put numbers on the repayment. The analysis states the state's general fund cost would be "$500 million to $600 million annually for about 20 years" [s2].
The analysis does not give a single total-with-interest figure. Instead it frames the premium of borrowing this way: the total cost "would be about 10 percent more (after adjusting for inflation) than if the state paid up-front with money it already has" [s2].
That framing is the practical meaning of a general obligation bond. The state sells bonds to investors, receives the $8.4 billion to spend on the research, and then repays investors with interest out of its general fund — the same pool of money used for schools, health programs and other services [s2]. Spreading roughly $500 million to $600 million of that repayment across about 20 years is what turns an up-front price tag into a two-decade commitment, and the inflation-adjusted premium is the cost of borrowing rather than paying cash [s2].
Why the structure is the story
Two design choices distinguish this measure. The first is that half the money is routed to one institute selected by a state agency, with a required UC-campus collaboration, rather than distributed entirely by open competition [s2]. The second is the scale and duration of the commitment: an $8.4 billion borrowing repaid at roughly half a billion dollars a year for about two decades [s2].
Those are the features that determine what the measure actually does with public money, as opposed to the broad label of "medical research" in its title.
What this article is not
This is a factual description of the measure and the Legislative Analyst's fiscal estimate. It is not an assessment of whether the research would succeed, whether the funding model is sound, or how anyone should vote.
What to watch
If the measure passes, the consequential details will be which institute the Department of Public Health designates, how the UC-collaboration requirement is met, and how the council structures the competitive-grant half of the funds [s2].
Sources
- Proposition 38 — Official Voter Information Guide — California Secretary of State
- Proposition 38 — Analysis by the Legislative Analyst — California Secretary of State / Legislative Analyst's Office
- Qualified Statewide Ballot Measures — California Secretary of State
What a 'gain of function' study is, and what the actual debate is about
The phrase is used loosely and argued about fiercely. At its core is a genuine dilemma: experiments that make a pathogen more dangerous can also be the ones that warn us fastest.
FDA drops a hepatitis B blood test where two others are run
Final FDA guidance published on 3 November says blood collectors need not test whole-blood donations for hepatitis B surface antigen when nucleic-acid and anti-core tests are run, keeping both for Source Plasma.
A hospital-based voter drive reached a younger, more diverse group than campaigns did
Of 12,441 people registered in US health care settings in 2020, 41.9% were aged 18 to 29. Their turnout rose from 61.0% in 2016 to 79.8% in 2020 — but this is a descriptive comparison, not a controlled trial.
Chronic illness tracks with whether people vote — and the direction is not uniform
A US survey and a Finnish register study agree that health shapes turnout, but not in one direction: diabetes was linked to higher voting, dementia to markedly lower. Both are associations, not proof.